Precision Medicine Then and Now: We Talk with the Retiring President of the Personalized Medicine Coalition, Ed Abrahams

·28 min·2 clips

Ed Abrahams, retiring after 20 years leading personalized medicine advocacy, reflects on what the field got right and wrong.

Host Theral Timpson interviews Ed Abrahams, who is retiring after 20 years as president of the Personalized Medicine Coalition. Abrahams begins by reflecting on the historical context of precision medicine, starting with President Clinton's 2000 announcement of the human genome sequencing. He compares the hype then to current AI excitement, noting that progress has been slower than expected but still significant. Abrahams highlights that over 300 drugs with biomarker strategies are now on the market, up from fewer than five in 2000. The discussion shifts to challenges, with Abrahams arguing that human factors like regulation, reimbursement, and clinical adoption are harder to solve than scientific ones. He points to diagnostics as a key area where tensions exist between industry preferences for low regulation and FDA demands for clinical validity. Abrahams mentions the Inflation Reduction Act as a potential negative impact on drug development. He also discusses the Personalized Medicine Coalition's role in bringing stakeholders together, such as through the congressional caucus. Examples like non-small cell lung cancer illustrate adoption gaps, where over 60% of patients don't receive targeted therapies. Abrahams calls for experiments with real-world evidence and AI to expedite progress. The episode concludes with a look forward, emphasizing the need for education and trust-building among payers, manufacturers, and providers.

As heard by us

A steady, practical look at why precision medicine still needs bridges from discovery to patient care.

Precision medicine comes across here as a field with real scientific momentum, but also with a stubborn last-mile problem: turning promising discoveries into care that patients can actually receive.

Read the full review in PlayNext →

Why you'd press play

You will hear a measured look back at personalized medicine with Ed Abrahams as he weighs a field with strong science, broader industry backing, and stubborn adoption problems still in the way.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Mendelspod Podcast